A detailed history of Quadrant Capital Group LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 29,838 shares of ABCL stock, worth $87,126. This represents 0.01% of its overall portfolio holdings.

Number of Shares
29,838
Previous 1,052 2736.31%
Holding current value
$87,126
Previous $3,000 2466.67%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.39 - $3.49 $68,798 - $100,463
28,786 Added 2736.31%
29,838 $77,000
Q2 2024

Aug 12, 2024

BUY
$2.73 - $4.73 $1,648 - $2,856
604 Added 134.82%
1,052 $3,000
Q1 2024

May 15, 2024

SELL
$4.29 - $5.97 $6,670 - $9,283
-1,555 Reduced 77.63%
448 $2,000
Q4 2023

Feb 08, 2024

BUY
$3.91 - $5.93 $4,383 - $6,647
1,121 Added 127.1%
2,003 $11,000
Q2 2023

Aug 09, 2023

BUY
$5.66 - $7.59 $4,992 - $6,694
882 New
882 $5,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $833M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.